drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous CD19-directed chimeric antigen receptor T-cell therapy; patient T cells engineered to express an anti-CD19 CAR with CD3zeta and costimulatory domains that, upon antigen engagement, activate T-cell signaling, expansion, cytokine release, and cytotoxic killing of CD19+ B-lineage leukemia cells; expected on-target B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti‑CD19 chimeric antigen receptor with CD3ζ and costimulatory domains. CAR engagement of CD19 on B‑lineage leukemic cells triggers T‑cell activation, proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxic killing, leading to clearance of CD19+ blasts and on‑target B‑cell aplasia.
drug_name
INS19 CAR-T Cells
nct_id_drug_ref
NCT06209671